Nanocarriers: a Versatile Approach for Mucosal Vaccine Delivery

References

• Wang J Thorson L Stokes RW Santosuosso M Huygen K Zganiacz A et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol.173 (10), 6357–6365 (2004).
   PubMed Web of Science ®Google Scholar
• Neutra MR Kozlowski PA . Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol.6 (2), 148–158 (2006).
   PubMed Web of Science ®Google Scholar
• Chadwick S Kriegel C Amiji M . Nanotechnology solutions for mucosal immunization. Adv. Drug Del. Rev.62 (4–5), 394–407 (2010).
   PubMed Web of Science ®Google Scholar
• Hobson P Barnfield C Barnes A Klavinskis LS . Mucosal immunization with DNA vaccines. Methods31 (3), 217–224 (2003).
   PubMed Web of Science ®Google Scholar
• Csaba N Garcia-Fuentes M Alonso MJ . Nanoparticles for nasal vaccination. Adv. Drug Deliv. Rev.61 (2), 140–157 (2009).
   PubMed Web of Science ®Google Scholar
• Jain S Khomane K Jain AK Dani P . Nanocarriers for transmucosal vaccine delivery. Current Nanosci.7, 160–177 (2011).
   Web of Science ®Google Scholar
• Amorij JP Saluja V Petersen AH Hinrichs WL Huckriede JA Frijlink HW . Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine25 (52), 8707–8717 (2007).
   PubMed Web of Science ®Google Scholar
• Vyas SP Gupta PN . Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev. Vaccines6 (3), 401–418 (2007).
   PubMed Web of Science ®Google Scholar
• Corr S Gahan CCGM Hill C . M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol. Med. Microbiol.52 (1), 2–12 (2008).
   PubMedGoogle Scholar
• Lawson LB Norton EB Clements JD . Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Currt. Opinion Immunol.23 (3), 414–420 (2011).
   PubMed Web of Science ®Google Scholar
• Cesta MF . Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol. Pathol.34 (5), 599–608 (2006).
   PubMed Web of Science ®Google Scholar
• Kunisawa J Nochi T Kiyono H . Immunological commonalities and distinctions between airway and digestive immunity. Trends Immunol.29 (11), 505–513 (2008).
   PubMed Web of Science ®Google Scholar
• Chen W Patel GB Yan H Zhang J . Recent advances in the development of novel mucosal adjuvants and antigen delivery systems. Hum. Vaccin.6 (9), 781–794 (2010).
   Google Scholar
• Mowat AM Millington OR Chirdo FG . Anatomical and cellular basis of immunity and tolerance in the intestine. J. Pediatr. Gastroenterol. Nutr.39 (Suppl.3), s723–s724 (2004).
   PubMed Web of Science ®Google Scholar
• Lycke N . Recent progress in mucosal vaccine development: potential and limitations. Nature Rev. Immunol.12 (8), 592–605 (2012).
   PubMed Web of Science ®Google Scholar
• Czerkinsky C Holmgren J . Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr. Top. Microbiol. Immunol.354, 1–18 (2010).
   Web of Science ®Google Scholar
• Levine MM . Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. doi:10.1186/1741-7007-8-129 (2010) ( Epub).
   PubMed Web of Science ®Google Scholar
• Kasturi SP Skountzou I Albrecht RA Koutsonanos D Hua TH Nakaya HI et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature470 (7335), 543–547 (2011).
   PubMed Web of Science ®Google Scholar
• Laroui H Wilson DS Dalmasso G Salaita K Murthy N Sitaraman SV et al. Nanomedicine in GI. Am. J. Physiol. Gastrointest. Liver Physiol.300 (3), g371–g383 (2011).
   PubMed Web of Science ®Google Scholar
• Cario E . Nanotechnology-based drug delivery in mucosal immune diseases: hype or hope?Mucosal Immuno.5, 2–3 (2012).
   Web of Science ®Google Scholar
• Farokhzad OC Langer R . Impact of nanotechnology on drug delivery. ACS Nano.3 (1), 16–20 (2009).
   PubMed Web of Science ®Google Scholar
• Gupta PN Mahor S Rawat A Khatri K Goyal A Vyas SP . Lectin anchored stabilized biodegradable nanoparticles for oral immunization 1. Development and in vitro evaluation. Int. J. Pharm.318 (1–2), 163–173 (2006).
   PubMedGoogle Scholar
• Shahiwala A Vyas TK Amiji MM . Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat. Drug Deliv. Formul.1 (1), 1–9 (2007).
   PubMedGoogle Scholar
• Csaba N Garcia-Fuentes M Alonso MJ . The performance of nanocarriers for transmucosal drug delivery. Expert Opin. Drug Deliv.3 (4), 463–478 (2006).
   PubMedGoogle Scholar
• Stuart LM Ezekowitz RAB . Phagocytosis elegant complexity. Immunity22 (5), 539–550 (2005).
   PubMed Web of Science ®Google Scholar
• Rajapaksa TE Lo DD . Microencapsulation of vaccine antigens and adjuvants for mucosal targeting. Curr. Immunol. Rev.6 (1), 29–37 (2010).
   Google Scholar
• Hartikka J Bozoukova V Ferrari M Sukhu L Enas J Sawdey M et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine19 (15–16), 1911–1923 (2001).
   PubMed Web of Science ®Google Scholar
• Thanou M Verhoef JC Junginger HE . Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Deliv. Rev.50 (Suppl.1), s91–s101 (2001).
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I Lin W Kistner O Davis SS Illum L . Polymeric lamellar substrate particles for intranasal vaccination. Adv. Drug Deliv. Rev.51 (1–3), 97–111 (2001).
   PubMed Web of Science ®Google Scholar
• Hejazi R Amiji M . Chitosan-based gastrointestinal delivery systems. J. Control Release89, 151–165 (2003).
   PubMed Web of Science ®Google Scholar
• Ye T Yue Y Fan X Dong C Xu W Xiong S . M cell-targeting strategy facilitates mucosal immune response and enhances protection against CVB3-induced viral myocarditis elicited by chitosan DNA vaccine. Vaccine32 (35), 4457–4465 (2014).
   PubMed Web of Science ®Google Scholar
• Vila A Sanchez A Evora C Soriano I Jato JLV Alonso MJ . PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J. Aerosol Med.17, 174–185 (2004).
   PubMedGoogle Scholar
• Primard C Poecheim J Heuking S Sublet E Esmaeili F Gerrit Borchard . Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic immunomodulator for mucosal immunization. Mol. Pharm.10 (8), 2996–3004 (2013).
   PubMed Web of Science ®Google Scholar
• Mangal S Pawar D Agrawal U Jain AK Vyas SP . Evaluation of mucoadhesive carrier adjuvant: toward an oral anthrax vaccine. Artif. Cells Nanomed. Biotechnol.42 (1), 47–57 (2014).
   PubMed Web of Science ®Google Scholar
• Mishra N Khatri K Gupta M Vyas SP . Development and characterization of LTA-appended chitosan nanoparticles for mucosal immunization against hepatitis B. Artif. Cells Nanomed. Biotechnol.42 (4), 245–255 (2014).
   PubMed Web of Science ®Google Scholar
• Flanary S Hoffman AS Stayton PS . Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconjug. Chem.20 (2), 241–248 (2009).
   PubMed Web of Science ®Google Scholar
• Hubbell JA Thomas SN Swartz MA . Materials engineering for immunomodulation. Nature462 (7272), 449–460 (2009).
   PubMed Web of Science ®Google Scholar
• Watson Douglas S Aaron N Huang EL . Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine30 (13), 2256–2272 (2012).
   PubMed Web of Science ®Google Scholar
• Nordly P Madsen HB Nielsen HM Foged C . Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert Opin. Drug Deliv.6 (7), 657–672 (2009).
   PubMed Web of Science ®Google Scholar
• Zhou F Neutra MR . Antigen delivery to mucosa-associated lymphoid tissues using liposomes as a carrier. Biosci. Rep.22 (2), 355–369 (2002).
   PubMed Web of Science ®Google Scholar
• Espuelas S Roth A Thumann C et al. Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells. Mol. Immunol.42 (6), 721–729 (2005).
   PubMed Web of Science ®Google Scholar
• Heurtault B Frisch B Pons F . Liposomes as delivery systems for nasal vaccination: strategies and outcomes. Expert Opin. Drug Deliv.7 (7), 829–844 (2010).
   PubMed Web of Science ®Google Scholar
• Gupta PN Vyas SP . Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization. Colloids Surf. B. Biointerfaces82 (1), 118–125 (2011).
   PubMed Web of Science ®Google Scholar
• Tiwari S Agrawal GP Vyas SP . Molecular basis of the mucosal immune system: from fundamental concepts to advances in liposome-based vaccines. Nanomedicine (Lond).5 (10), 1617–1640 (2010).
   PubMed Web of Science ®Google Scholar
• Tiwari S Verma SK Agrawal GP Vyas SP . Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen. Inter. J. Pharma.413, 211–219 (2011).
   PubMed Web of Science ®Google Scholar
• Zhuang Y Ma Y Wang C Hai L Yan C Zhang Y et al. PEGylated cationic liposomes robustly augment vaccine-induced immune responses: role of lymphatic trafficking and biodistribution. J. Control Release159 (1), 135–142 (2012).
   PubMed Web of Science ®Google Scholar
• Senchi KM Hasegawa S Kimura H Ryo H . Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3. Front Microbiol.26 (4), 346 (2013).
   Google Scholar
• Henderson A Propst K Kedl R Dow S . Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity. Vaccine29 (32), 5304–5312 (2011).
   PubMed Web of Science ®Google Scholar
• Wang HW Jiang PL Lin S Lin HJ Liang Ou K Deng W et al. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization. Acta Biomater.9 (3), 5681–5688 (2013).
   PubMed Web of Science ®Google Scholar
• Watarai S Iwase T Tajima T Yuba E Kono K Sekiya Y . Application of pH-sensitive fusogenic polymer-modified liposomes for development of mucosal vaccines. Vet. Immunol. Immunopathol.158 (1–2), 62–72 (2014).
   PubMed Web of Science ®Google Scholar
• de Veer M Neeland M Burke M et al. Cell recruitment and antigen trafficking in afferent lymph after injection of antigen and poly(I:C) containing liposomes, in aqueous or oil-based formulations. Vaccine31 (7), 1012–1018 (2013).
   PubMed Web of Science ®Google Scholar
• Herzog C Hartmann K Kunzi V Kursteiner O Mischler R Lazar H et al. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine27 (33), 4381–4387 (2009).
   PubMed Web of Science ®Google Scholar
• Kursteiner O Mischler R Metcalfe IC . Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine20 (Suppl.5), b17–b23 (2002).
   PubMedGoogle Scholar
• Bovier PA . Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev. Vaccines7 (8), 1141–1150 (2008).
   PubMed Web of Science ®Google Scholar
• Usonis V Bakasenas V Valentelis R Katiliene G Vidzeniene D Herzog C . Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine21 (31), 4588–4592 (2003).
   PubMed Web of Science ®Google Scholar
• Butts C Murray N Maksymiuk A Goss G Marshall E Soulieres D et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol.23 (27), 6674–6681 (2005).
   PubMed Web of Science ®Google Scholar
• North S Butts C . Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev. Vaccines4 (3), 249–257 (2005).
   PubMed Web of Science ®Google Scholar
• Regules JA Cummings JF Ockenhouse CF . The RTS, S vaccine candidate for malaria. Expert Rev. Vaccines10 (5), 589–599 (2011).
   PubMed Web of Science ®Google Scholar
• Agnandji ST Asante KP Lyimo J Vekemans J Soulanoudjingar SS Owusu R et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J. Infect. Dis.202 (7), 1076–1087 (2010).
   PubMed Web of Science ®Google Scholar
• Schoenen H Bodendorfer B Hitchens K Manzanero S Werninghaus K Nimmerjahn F et al. Cutting edge: mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J. Immunol.184 (6), 2756–2760 (2010).
   PubMed Web of Science ®Google Scholar
• Even-Or O Joseph A Itskovitz-Cooper N Samira S Rochlin E Eliyahu H et al. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity. Vaccine29 (13), 2474–2486 (2011).
   PubMed Web of Science ®Google Scholar
• Even-Or O Samira S Rochlin E Balasingam S Mann AJ Lambkin-Williams R et al. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine. Vaccine28 (39), 6527–6541 (2010).
   PubMed Web of Science ®Google Scholar
• Lay M Callejo B Chang S Hong DK Lewis DB Carroll TD et al. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine27 (29), 3811–3820 (2009).
   PubMed Web of Science ®Google Scholar
• Sullivan SM Doukas J Hartikka J Smith L Rolland A . Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin. Drug Deliv.7 (12), 1433–1446 (2010).
   PubMed Web of Science ®Google Scholar
• Jain S Singh P Mishra V Vyas SP . Mannosylated niosomes as adjuvant–carrier system for oral genetic immunization against hepatitis B. Immunol. Lett.101 (1), 41–49 (2005).
   PubMed Web of Science ®Google Scholar
• Wilkhu JS McNeil SE Anderson DE Perrie Y . Characterization and optimization of bilosomes for oral vaccine delivery. J. Drug Target.21 (3), 291–299 (2013).
   PubMed Web of Science ®Google Scholar
• Shilpa S Srinivasan BP Chauhan M . Niosomes as vesicular carriers for delivery of proteins and biologicals. Inter. J. Drug Deliv.3 (1), 14–24 (2011).
   Google Scholar
• Cortesi R Ravani L Rinaldi F Marconi P Drechsler M Manservigi M et al. Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes. Int. J. Pharm.440 (2), 229–237 (2013).
   PubMedGoogle Scholar
• Pardakhty A Shakibaie M Daneshvar H Khamesipour A Mohammadi-Khorsand T Forootanfar H . Preparation and evaluation of niosomes containing autoclaved Leishmania major: a preliminary study. J. Microencapsul.29 (3), 219–224 (2012).
   PubMed Web of Science ®Google Scholar
• Jain S Vyas SP . Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization. J. Liposome Res.16 (4), 331–345 (2006).
   PubMed Web of Science ®Google Scholar
• Katare R Gupta PN Mahor S et al. Development of polysaccharide-capped niosomes for oral immunization of tetanus toxoid. J. Drug Deliv. Sci. Technol.16 (3), 167–172 (2006).
   Web of Science ®Google Scholar
• Mann JFS Ferro VA Mullen AB Tetley L Mullen M Carter KC Alexander J Stimson WH . Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin. Vaccine22 (19), 2425–2429 (2004).
   PubMed Web of Science ®Google Scholar
• Mann JFS Scales HE Shakir E Alexander J Cartera KC Mullen AB et al. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods38 (2), 90–95 (2006).
   PubMed Web of Science ®Google Scholar
• Conacher M Alexander J Brewer J . Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine19 (20–22), 2965–2974 (2001).
   PubMed Web of Science ®Google Scholar
• Arora D Khurana B Murugesan SM Vyas SP . Oral immunization against hepatitis B virus using mannosylated bilosomes. Inter. J. Recent Adv. Pharma. Res.1, 45–51 (2011).
   Google Scholar
• Premanand B Prabakaran M Kiener TK Kwang J . Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice. PLoS ONE8 (2), e55536 (2013).
   PubMed Web of Science ®Google Scholar
• Jain S Harde H Indulkar A Agrawal AK . Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. Nanomedicine10 (2), 431–440 (2014).
   PubMed Web of Science ®Google Scholar
• Wilschut J . Influenza vaccines: the virosome concept. Immunol. Lett.122 (2), 118–121 (2009).
   PubMed Web of Science ®Google Scholar
• Huckriede A Bungener L Stegmann T Daemen T Medema J Palache AM Wilschut J . The virosome concept for influenza vaccines. Vaccine23 (Supple.1), s26–s38 (2005).
   PubMedGoogle Scholar
• Durrer P Glück U Spyr C Lang AB Zurbriggen R Herzog C et al. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine21 (27–30), 4328–4334 (2003).
   PubMed Web of Science ®Google Scholar
• Lambkin R Oxford JS Bossuyt S Mann A Metcalfe IC Herzog C et al. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine. Vaccine22 (31–32), 4390–4396 (2004).
   PubMed Web of Science ®Google Scholar
• Morgane B Daniela T Drillet AS Alfsen A Ganor Y Roger MG et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal HIV. Immunity34 (2), 269–280 (2011).
   PubMed Web of Science ®Google Scholar
• Liu J Gong T Fu H Wang C Wang X Chen Q Zhang Q He Q Zhang Z . Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm.356 (1–2), 333–344 (2006).
   Google Scholar
• Pedersen N Hansen S Heydenreich AV Kristensen HG Poulsen HS . Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur. J. Pharm. Biopharm.62 (2), 155–162 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang N Ping Q Huang G Hu W Cheng Y Han X . Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm.327 (1–2), 153–159 (2006).
   PubMed Web of Science ®Google Scholar
• Saraf S Mishra D Asthana A Jain R Singh S Jain NK . Lipid microparticles for mucosal immunization against hepatitis B. Vaccine24 (1), 45–56 (2006).
   PubMed Web of Science ®Google Scholar
• Pushechnikov A Jalisatgi AA Hawthorne MF . Dendritic closomers: novel spherical hybrid dendrimers. Chem. Commun (Camb).49 (34), 3579–3581 (2013).
   PubMed Web of Science ®Google Scholar
• Misumi S Masuyama M Takamune N Nakayama D Mitsumata R Matsumoto H Urata N Takahashi Y Muneoka A Sukamoto T Fukuzaki K Shoji S . Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer. J. Immunol.182 (10), 6061–6070 (2009).
   PubMed Web of Science ®Google Scholar
• Solans C Izquierdo P Nolla J Azemar N Garcia-Celma MJ . Nano-emulsions. Curr. Opin. Colloid Interface Sci.10 (3–4), 102–110 (2005).
   Web of Science ®Google Scholar
• Muller RH Mader K Gohla S . Solid lipid nanoparticles for controlled drug delivery–a review of the state of the art. Eur. J. Pharm. Biopharm.50 (1), 161–177 (2000).
   PubMed Web of Science ®Google Scholar
• Baker JR Bielinska A Landers J Janczak K Cao P . Enhanced systemic and mucosal immune responses in mice immunized with recombinant Bacillus anthracis protective antigen (rPA) using a novel nanoemulsion adjuvant. J. Allergy Clin. Immunol.113 (2), 292–292 (2004).
   Google Scholar
• Makidon PE Bielinska AU Nigavekar SS Janczak KW Knowlton J . Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS ONE3 (8), e2954 (2008).
   PubMed Web of Science ®Google Scholar